Enhanced Anticancer Effect of a Combination of S-adenosylmethionine (SAM) and Immune Checkpoint Inhibitor (ICPi) in a Syngeneic Mouse Model of Advanced Melanoma

Immune checkpoint inhibitors (ICPi) targeting the PD-1/PD-L1 pathway have shown marked success in patients with advanced melanoma. However, 60–70% of patients fail to respond, warranting a therapeutic intervention that could increase response rates. We and others have shown that S-adenosylmethionine...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehdi, Ali, Attias, Mikhael, Mahmood, Niaz, Arakelian, Ani, Mihalcioiu, Catalin, Piccirillo, Ciriaco A., Szyf, Moshe, Rabbani, Shafaat Ahmed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492272/
https://www.ncbi.nlm.nih.gov/pubmed/32983966
http://dx.doi.org/10.3389/fonc.2020.01361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492272/
https://www.ncbi.nlm.nih.gov/pubmed/32983966
http://dx.doi.org/10.3389/fonc.2020.01361

Ejemplares similares